Classical protein kinase C (cPKC)

Classical protein kinase C (cPKC) isoforms, including PKC-alpha, PKC-beta, and PKC-gamma, are a subgroup of the PKC family of serine/threonine kinases that require calcium, diacylglycerol (DAG), and phospholipids for activation (UniProt P17252, P05771, P05129). These enzymes play a pivotal role in various signal transduction pathways, translating extracellular signals into cellular responses such as proliferation, differentiation, and apoptosis (PubMed PMID: 23913112). In disease states, cPKCs are often dysregulated; for instance, PKC-beta is heavily implicated in diabetic microvascular complications like retinopathy, while PKC-alpha is frequently overexpressed in various cancers (PubMed PMID: 16900518). Therapeutic strategies targeting cPKCs have primarily focused on small-molecule inhibitors, such as ruboxistaurin for diabetic complications and enzastaurin for oncology, though achieving high isoform selectivity remains a significant challenge (PubChem CID 9830483). Recent research also highlights the complex role of PKCs as potential tumor suppressors in some contexts, suggesting that both inhibition and activation might be therapeutically relevant depending on the specific pathology (PubMed PMID: 25619686). Beyond cancer and diabetes, cPKCs are involved in cardiovascular functions and neuroplasticity, making them targets for a wide range of conditions including heart failure and Alzheimer's disease (PubMed PMID: 26721424). The development of drugs targeting these isoforms must navigate the high structural homology between PKC members to avoid unwanted side effects (PubMed PMID: 23913112).

Other names

Conventional protein kinase CCalcium-dependent protein kinase CcPKCProtein kinase C alphaProtein kinase C betaProtein kinase C gammaPRKCAPRKCBPRKCG

ATP-competitive inhibition of the catalytic domain or modulation of the regulatory C1/C2 domains to prevent activation by diacylglycerol and calcium.